91视频

• Biography/ Background

  Mr Tamblyn has more than 10 years' experience in the critical appraisal of evidence for health technology assessment across a broad range of services. He is involved in the evaluation of submissions for devices and pharmaceutical to the TGA for regulatory purposes, the evaluation of submissions for pharmaceuticals to the Pharmaceutical Benefits Advisory Committee, and the evaluation of medical services submitted to the Medical Benefits Advisory Committee. Mr Tamblyn supports and manages staff performing such assessments and provides quality assurance of deliverables.

  Regulatory assessments of Devices

  Evaluation of the safety and performance of devices (including application audits and conformity assessments) for the Therapeutic Goods Administration. Evaluations involve the synthesis of pre-clinical data, clinical data, published studies, registry and post market surveillance data, risk management plans and activities, and the audit of product information or similar documents provided to health care practitioners and patients. Common indications for devices assessed are: orthopaedics, ophthalmology, cardiology, interventional radiology, pain management.

  Regulatory assessments of Oncology Drugs

  Evaluation of the safety, efficacy and pharmacology of new oncology drugs for the Therapeutic Goods Administration for regulatory purposes. Evaluations involve the assessment of the quality of the clinical evidence (Module 5) of a pharmaceutical, which is synthesised into a benefit / risk profile, and a recommendation to the ACM and/or TGA delegate.

  Assessments of pharmaceuticals for reimbursement

  Evaluation of the safety, effectiveness and cost-effectiveness of pharmaceuticals across a range of clinical areas for the Pharmaceutical Benefits Advisory Committee (PBAC) for the purposes of establishing suitability for reimbursement on the PBS. Evaluations involve the assessment of clinical and economic evidence, and of the financial impact to the Australian health care system.

  Assessments of medical services for reimbursement

  Evaluation of the safety, effectiveness and cost-effectiveness of medical services, including co-dependent testing, molecular and genetic testing, imaging, programs and therapeutic procedures, for the Medical Services Advisory Committee (MSAC) for the purposes of establishing suitability for reimbursement on the MBS. Evaluations involve the assessment of clinical and economic evidence, and of the financial impact to the Australian health care system.

  Additional expertise

  Mr Tamblyn has been involved in a range of projects relating to HTA, including broader reviews and development of methodology. These projects include:

  • Co-lead researcher for "Guidelines for preparing assessments for the Medical Services Advisory Committee, Version 1.0, May 2021"
  • Co-lead researcher for "Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0, September 2016"
  • Review of an Australian lung cancer screening program
  • Guidance for the evaluation of tumour type agnostic therapies
  • Review of a class of devices for the TGA
  • Review of the Life Saving Drugs Programme
  • Review of MBS Items for specific ophthalmology services under the MBS Quality Framework
  • Review of the Statins Therapeutic Group
  • Vertebroplasy / Kyphoplasty for the treatment of vertebral compression fracture
  • Brachytherapy for the treatment of prostate cancer
  • National Evidence Based Guidelines for the Prevention, Identification and Management of Foot Complications in Diabetes

  Teaching

  Mr Tamblyn has contributed to teaching in the School of Public Health and the School of Medicine in epidemiology and health economics.

• Qualifications

  University Qualifications:

  Master of Public Health, University of Adelaide (2011)

  Bachelor of Health Science, University of Adelaide (2001)

  Courses:

  University Teaching for Effective Student Learning, University of Adelaide, 2014

  MAEFA courses: Quantitative Analysis using Stata 13, Working Efficiently with Stata 13, Programming with Stata 13, Raw Data Management with Stata 13

  TreeAge Pro Training: Cost-effectiveness models, Markov models and Micro-simulation

  Survival Analysis short course (Monash)

  Modelling Methods for Health Economic Evaluations (University of York, McMaster University collaboration)

  Introduction to Network Meta-analysis / Mixed treatment comparisons (CADTH)

• Publications

  Peer reviewed publications

  Leach, Damien A., Eleanor F. Need, Roxanne Toivanen, Andrew P. Trotta, Helen M. Palenthorpe, David J. Tamblyn, Tina Kopsaftis et al. "Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome." Oncotarget (2015).

  Merlin, Tracy, David Tamblyn, and Benjamin Ellery. "What's in a name? Developing definitions for common health technology assessment product types of the international network of agencies for health technology assessment (INAHTA)." International journal of technology assessment in health care (2014): 1-8.

  Tamblyn, DJ, Chopra, S, Yu, C, Kattan, MW, Pinnock, C & Kopsaftis, T 2011, 'Comparative analysis of three risk assessment tools in Australian patients with prostate cancer', BJU International, vol. 108, pp. 51-56.

  Beckmann, K, Pinnock, CB, Tamblyn, DJ, Kopsaftis, T, Stapleton, AMF & Roder, DM 2009, 'Clinical and socio-demographic profile of an Australian multi-institutional prostate cancer cohort', Asia-Pacific Journal of Clinical Oncology, vol. 5, no. 4, pp. 247-256.

  Stapleton, AM, Johns, RL, Kopsaftis, T, Tamblyn, DJ & Pinnock, CB 2008, 'Abnormal PSA tests--delays in referral', Aust Fam Physician, vol. 37, no. 1-2, Jan-Feb, pp. 84-88.

  
  Selected contracted reports

  Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0. September 2016. Commonwealth of Australia, Canberra, ACT.

  Tamblyn, DJ, Ellery, B & Merlin, T 2011, Brachytherapy for the treatment of prostate cancer. MSAC Application 1089.1, Review of Interim Funded Service, Commonwealth of Australia, Canberra, ACT.

  Doidge, J, Merlin, T, Liufu, Z, Tamblyn, DJ, Jia, LY & Hiller, JE 2011, Review of interim funded service: Vertebroplasty and new review of Kyphoplasty. MSAC Application 27.1, Commonwealth of Australia, Canberra, ACT.

  Morona, JK, Newton, S, Wang, S, Tamblyn, DJ, Ellery, B & Merlin, T 2014, Genetic testing for hereditary mutations in the VHL gene that cause von Hippel-Lindau syndrome. MSAC Application 1153, Assessment Report., Commonwealth of Australia, Canberra, ACT.

  Merlin, T, Street, J, Holton, C, Mundy, L, Tamblyn, DJ, Ellery, B, Juneja, V, Reddin, E, Scrimgeour, S & Hennessy, S 2011, Review of MBS Items for specific ophthalmology services under the MBS Quality Framework., Commonwealth of Australia, Canberra, ACT.

• Professional Associations

  Deputy Editor, International Journal of Technology Assessment in Health Care https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care

  Committee Member, South Australian Policy Advisory Committee on Technology (SAPACT)

  Committee Member, South Australian Medicines Evaluation Panel (SAMEP)

  Working Group Member, TGA Expert Working Group for Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) 

  Agency Member, International Network of Agencies for Health Technology Assessment (INAHTA)

  Individual Member, Health Technology Assessment International (HTAi)

Entry last updated: Saturday, 21 May 2022

To link to this page, please use the following URL:  /directory/david.tamblyn